Details of the Drug Combination

General Information of Drug Combination (ID: DC5K5SB)

Drug Combination Name
F901318 Posaconazole
Indication
Disease Entry Status REF
Invasive Aspergillosis Phase 1 [1]
Component Drugs F901318   DM2CUS0 Posaconazole   DMUL5EW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of F901318
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Phase 2 [2]
F901318 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) TTTSUI2 G5EB61_EMENI Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Posaconazole
Disease Entry ICD 11 Status REF
Aspergillosis 1F20 Approved [3]
Candidiasis 1F23 Approved [4]
Chromomycosis N.A. Approved [4]
Coccidioidomycosis 1F25 Approved [4]
Fusariosis N.A. Approved [4]
Posaconazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Inhibitor [6]
------------------------------------------------------------------------------------
Posaconazole Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Posaconazole Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
Posaconazole Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [10]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [11]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Decreases Activity [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03095547) Drug/Drug Interactions With F901318
2 ClinicalTrials.gov (NCT03583164) Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS). U.S. National Institutes of Health.
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022003.
4 Posaconazole FDA Label
5 Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18.
6 A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
7 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
8 Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70.
9 Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004 Feb;32(2):267-71.
10 Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol. 2009 Apr;31(4):292-5. doi: 10.1097/MPH.0b013e31819b9d01.
11 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
12 Inhibition of 11-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. Biochem Pharmacol. 2017 Apr 15;130:93-103. doi: 10.1016/j.bcp.2017.01.010. Epub 2017 Jan 25.